TWI333958B - - Google Patents

Download PDF

Info

Publication number: TWI333958B
Authority: TW; Taiwan
Prior art keywords: gpc3; peptide; cell; fmoc; hla
Prior art date: 2002-08-26

Application number

TW092122744A

Other languages

English (en)

Chinese (zh)

Other versions

TW200413406A (en

Inventor

Nishimura Yasuharu

Nakatsura Tetsuya

Yusuke Nakamura

Original Assignee

Oncotherapy Science Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-08-26

Filing date

2003-08-19

Publication date

2010-12-01

2003-08-19 Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc

2004-08-01 Publication of TW200413406A publication Critical patent/TW200413406A/zh

2010-12-01 Application granted granted Critical

2010-12-01 Publication of TWI333958B publication Critical patent/TWI333958B/zh

Links

108090000765 processed proteins & peptides Proteins 0.000 claims description 105
108090000623 proteins and genes Proteins 0.000 claims description 61
210000004027 cell Anatomy 0.000 claims description 54
238000000034 method Methods 0.000 claims description 44
206010028980 Neoplasm Diseases 0.000 claims description 42
150000001413 amino acids Chemical group 0.000 claims description 33
241000282414 Homo sapiens Species 0.000 claims description 24
210000000612 antigen-presenting cell Anatomy 0.000 claims description 24
230000001939 inductive effect Effects 0.000 claims description 24
108010013476 HLA-A24 Antigen Proteins 0.000 claims description 22
102000004196 processed proteins & peptides Human genes 0.000 claims description 17
229940024606 amino acid Drugs 0.000 claims description 16
238000011282 treatment Methods 0.000 claims description 13
239000000427 antigen Substances 0.000 claims description 12
108091007433 antigens Proteins 0.000 claims description 12
102000036639 antigens Human genes 0.000 claims description 12
210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 11
230000001472 cytotoxic effect Effects 0.000 claims description 10
230000001605 fetal effect Effects 0.000 claims description 10
210000001808 exosome Anatomy 0.000 claims description 9
230000002265 prevention Effects 0.000 claims description 8
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 7
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 7
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 6
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 6
231100000433 cytotoxic Toxicity 0.000 claims description 6
229930182817 methionine Natural products 0.000 claims description 6
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 6
239000006228 supernatant Substances 0.000 claims description 6
229920000669 heparin Polymers 0.000 claims description 5
229960002897 heparin Drugs 0.000 claims description 5
108050001154 Glypican Proteins 0.000 claims description 4
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 4
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 4
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 4
238000000338 in vitro Methods 0.000 claims description 4
229960000310 isoleucine Drugs 0.000 claims description 4
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 4
210000004185 liver Anatomy 0.000 claims description 4
210000004072 lung Anatomy 0.000 claims description 4
108050007237 Glypican-3 Proteins 0.000 claims description 3
108010075704 HLA-A Antigens Proteins 0.000 claims description 3
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 3
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 3
206010036790 Productive cough Diseases 0.000 claims description 3
210000003734 kidney Anatomy 0.000 claims description 3
210000002826 placenta Anatomy 0.000 claims description 3
210000003802 sputum Anatomy 0.000 claims description 3
208000024794 sputum Diseases 0.000 claims description 3
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 3
125000001433 C-terminal amino-acid group Chemical group 0.000 claims description 2
101001014668 Homo sapiens Glypican-3 Proteins 0.000 claims description 2
210000001072 colon Anatomy 0.000 claims description 2
210000001672 ovary Anatomy 0.000 claims description 2
239000008194 pharmaceutical composition Substances 0.000 claims description 2
238000013519 translation Methods 0.000 claims description 2
102100032530 Glypican-3 Human genes 0.000 claims 2
210000004556 brain Anatomy 0.000 claims 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims 1
102000011786 HLA-A Antigens Human genes 0.000 claims 1
210000000988 bone and bone Anatomy 0.000 claims 1
210000004907 gland Anatomy 0.000 claims 1
239000001963 growth medium Substances 0.000 claims 1
239000000411 inducer Substances 0.000 claims 1
210000000496 pancreas Anatomy 0.000 claims 1
210000000813 small intestine Anatomy 0.000 claims 1
210000000952 spleen Anatomy 0.000 claims 1
210000001562 sternum Anatomy 0.000 claims 1
210000001550 testis Anatomy 0.000 claims 1
210000001541 thymus gland Anatomy 0.000 claims 1
210000001685 thyroid gland Anatomy 0.000 claims 1
210000004291 uterus Anatomy 0.000 claims 1
206010073071 hepatocellular carcinoma Diseases 0.000 description 80
231100000844 hepatocellular carcinoma Toxicity 0.000 description 79
102000004169 proteins and genes Human genes 0.000 description 50
201000011510 cancer Diseases 0.000 description 21
210000002966 serum Anatomy 0.000 description 19
230000015572 biosynthetic process Effects 0.000 description 14
238000003786 synthesis reaction Methods 0.000 description 13
JAUKCFULLJFBFN-VWLOTQADSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[4-[(2-methylpropan-2-yl)oxy]phenyl]propanoic acid Chemical compound C1=CC(OC(C)(C)C)=CC=C1C[C@@H](C(O)=O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 JAUKCFULLJFBFN-VWLOTQADSA-N 0.000 description 12
241000711549 Hepacivirus C Species 0.000 description 12
230000014509 gene expression Effects 0.000 description 12
238000004458 analytical method Methods 0.000 description 11
239000011347 resin Substances 0.000 description 11
229920005989 resin Polymers 0.000 description 11
BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 10
239000012228 culture supernatant Substances 0.000 description 10
CBPJQFCAFFNICX-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-methylpentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(C)C)C(O)=O)C3=CC=CC=C3C2=C1 CBPJQFCAFFNICX-IBGZPJMESA-N 0.000 description 9
101100342977 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) leu-1 gene Proteins 0.000 description 9
239000003814 drug Substances 0.000 description 9
238000009169 immunotherapy Methods 0.000 description 9
239000000523 sample Substances 0.000 description 9
210000001519 tissue Anatomy 0.000 description 9
NTFTULBKHJJQAW-HNNXBMFYSA-N 9h-fluoren-9-ylmethyl n-[(2s)-4-methyl-1-oxopentan-2-yl]carbamate Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(C)C)C=O)C3=CC=CC=C3C2=C1 NTFTULBKHJJQAW-HNNXBMFYSA-N 0.000 description 8
108020004999 messenger RNA Proteins 0.000 description 8
238000005406 washing Methods 0.000 description 7
REITVGIIZHFVGU-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[(2-methylpropan-2-yl)oxy]propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](COC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 REITVGIIZHFVGU-IBGZPJMESA-N 0.000 description 6
241000700721 Hepatitis B virus Species 0.000 description 6
230000006698 induction Effects 0.000 description 6
SJVFAHZPLIXNDH-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-phenylpropanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C1=CC=CC=C1 SJVFAHZPLIXNDH-QFIPXVFZSA-N 0.000 description 5
OTKXCALUHMPIGM-FQEVSTJZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 OTKXCALUHMPIGM-FQEVSTJZSA-N 0.000 description 5
238000003745 diagnosis Methods 0.000 description 5
238000010647 peptide synthesis reaction Methods 0.000 description 5
238000003757 reverse transcription PCR Methods 0.000 description 5
238000012552 review Methods 0.000 description 5
229960004799 tryptophan Drugs 0.000 description 5
FODJWPHPWBKDON-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-[(2-methylpropan-2-yl)oxy]-4-oxobutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 FODJWPHPWBKDON-IBGZPJMESA-N 0.000 description 4
HNICLNKVURBTKV-NDEPHWFRSA-N (2s)-5-[[amino-[(2,2,4,6,7-pentamethyl-3h-1-benzofuran-5-yl)sulfonylamino]methylidene]amino]-2-(9h-fluoren-9-ylmethoxycarbonylamino)pentanoic acid Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)N[C@H](C(O)=O)CCCN=C(N)NS(=O)(=O)C1=C(C)C(C)=C2OC(C)(C)CC2=C1C HNICLNKVURBTKV-NDEPHWFRSA-N 0.000 description 4
QXVFEIPAZSXRGM-DJJJIMSYSA-N (2s,3s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-methylpentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H]([C@@H](C)CC)C(O)=O)C3=CC=CC=C3C2=C1 QXVFEIPAZSXRGM-DJJJIMSYSA-N 0.000 description 4
NDKDFTQNXLHCGO-UHFFFAOYSA-N 2-(9h-fluoren-9-ylmethoxycarbonylamino)acetic acid Chemical compound C1=CC=C2C(COC(=O)NCC(=O)O)C3=CC=CC=C3C2=C1 NDKDFTQNXLHCGO-UHFFFAOYSA-N 0.000 description 4
238000002965 ELISA Methods 0.000 description 4
-1 Heparin glycoside Chemical class 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
210000004443 dendritic cell Anatomy 0.000 description 4
238000001514 detection method Methods 0.000 description 4
239000000032 diagnostic agent Substances 0.000 description 4
229940039227 diagnostic agent Drugs 0.000 description 4
230000000694 effects Effects 0.000 description 4
210000005228 liver tissue Anatomy 0.000 description 4
238000002493 microarray Methods 0.000 description 4
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
229960005190 phenylalanine Drugs 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
238000012360 testing method Methods 0.000 description 4
238000001262 western blot Methods 0.000 description 4
KLBPUVPNPAJWHZ-UMSFTDKQSA-N (2r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-tritylsulfanylpropanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)SC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 KLBPUVPNPAJWHZ-UMSFTDKQSA-N 0.000 description 3
WDGICUODAOGOMO-DHUJRADRSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-5-oxo-5-(tritylamino)pentanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)CC(=O)NC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 WDGICUODAOGOMO-DHUJRADRSA-N 0.000 description 3
UMRUUWFGLGNQLI-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-6-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCCCNC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 UMRUUWFGLGNQLI-QFIPXVFZSA-N 0.000 description 3
108091016585 CD44 antigen Proteins 0.000 description 3
108010003471 Fetal Proteins Proteins 0.000 description 3
102000004641 Fetal Proteins Human genes 0.000 description 3
102000010956 Glypican Human genes 0.000 description 3
102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 description 3
229920002971 Heparan sulfate Polymers 0.000 description 3
241000699666 Mus <mouse, genus> Species 0.000 description 3
101710127914 Proteoglycan 3 Proteins 0.000 description 3
102100028964 Proteoglycan 3 Human genes 0.000 description 3
108090000054 Syndecan-2 Proteins 0.000 description 3
108010063628 acarboxyprothrombin Proteins 0.000 description 3
238000003556 assay Methods 0.000 description 3
230000006399 behavior Effects 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
238000009566 cancer vaccine Methods 0.000 description 3
229940022399 cancer vaccine Drugs 0.000 description 3
208000019425 cirrhosis of liver Diseases 0.000 description 3
239000002299 complementary DNA Substances 0.000 description 3
238000002405 diagnostic procedure Methods 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
210000003494 hepatocyte Anatomy 0.000 description 3
230000002998 immunogenetic effect Effects 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
229960003136 leucine Drugs 0.000 description 3
230000003211 malignant effect Effects 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
238000011002 quantification Methods 0.000 description 3
238000003127 radioimmunoassay Methods 0.000 description 3
230000000638 stimulation Effects 0.000 description 3
238000006467 substitution reaction Methods 0.000 description 3
238000001356 surgical procedure Methods 0.000 description 3
229960005486 vaccine Drugs 0.000 description 3
ZPGDWQNBZYOZTI-SFHVURJKSA-N (2s)-1-(9h-fluoren-9-ylmethoxycarbonyl)pyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 ZPGDWQNBZYOZTI-SFHVURJKSA-N 0.000 description 2
UGNIYGNGCNXHTR-SFHVURJKSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-methylbutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](C(C)C)C(O)=O)C3=CC=CC=C3C2=C1 UGNIYGNGCNXHTR-SFHVURJKSA-N 0.000 description 2
BUBGAUHBELNDEW-SFHVURJKSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-methylsulfanylbutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCSC)C(O)=O)C3=CC=CC=C3C2=C1 BUBGAUHBELNDEW-SFHVURJKSA-N 0.000 description 2
QWXZOFZKSQXPDC-NSHDSACASA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](C)C(O)=O)C3=CC=CC=C3C2=C1 QWXZOFZKSQXPDC-NSHDSACASA-N 0.000 description 2
KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 2
125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
206010016654 Fibrosis Diseases 0.000 description 2
ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 2
208000005176 Hepatitis C Diseases 0.000 description 2
XOWMDXHFSBCAKQ-SRVKXCTJSA-N Leu-Ser-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC(C)C XOWMDXHFSBCAKQ-SRVKXCTJSA-N 0.000 description 2
206010061309 Neoplasm progression Diseases 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
FKLSMYYLJHYPHH-UWVGGRQHSA-N Pro-Gly-Leu Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O FKLSMYYLJHYPHH-UWVGGRQHSA-N 0.000 description 2
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
210000001744 T-lymphocyte Anatomy 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
239000003875 Wang resin Substances 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
238000007792 addition Methods 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
229940025084 amphetamine Drugs 0.000 description 2
230000000692 anti-sense effect Effects 0.000 description 2
239000000872 buffer Substances 0.000 description 2
239000013592 cell lysate Substances 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
230000007882 cirrhosis Effects 0.000 description 2
230000008878 coupling Effects 0.000 description 2
238000010168 coupling process Methods 0.000 description 2
238000005859 coupling reaction Methods 0.000 description 2
DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 2
238000010511 deprotection reaction Methods 0.000 description 2
229940126864 fibroblast growth factor Drugs 0.000 description 2
238000000684 flow cytometry Methods 0.000 description 2
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
101150039713 gpc3 gene Proteins 0.000 description 2
208000002672 hepatitis B Diseases 0.000 description 2
238000002991 immunohistochemical analysis Methods 0.000 description 2
238000011534 incubation Methods 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
208000019423 liver disease Diseases 0.000 description 2
230000003908 liver function Effects 0.000 description 2
239000006166 lysate Substances 0.000 description 2
239000012528 membrane Substances 0.000 description 2
210000005259 peripheral blood Anatomy 0.000 description 2
239000011886 peripheral blood Substances 0.000 description 2
239000013641 positive control Substances 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
230000004044 response Effects 0.000 description 2
238000011269 treatment regimen Methods 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
239000000439 tumor marker Substances 0.000 description 2
230000005751 tumor progression Effects 0.000 description 2
ADOHASQZJSJZBT-SANMLTNESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[1-[(2-methylpropan-2-yl)oxycarbonyl]indol-3-yl]propanoic acid Chemical compound C12=CC=CC=C2N(C(=O)OC(C)(C)C)C=C1C[C@@H](C(O)=O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 ADOHASQZJSJZBT-SANMLTNESA-N 0.000 description 1
KJYAFJQCGPUXJY-UMSFTDKQSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-oxo-4-(tritylamino)butanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C(=O)NC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 KJYAFJQCGPUXJY-UMSFTDKQSA-N 0.000 description 1
KSDTXRUIZMTBNV-INIZCTEOSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)butanedioic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(=O)O)C(O)=O)C3=CC=CC=C3C2=C1 KSDTXRUIZMTBNV-INIZCTEOSA-N 0.000 description 1
LZOLWEQBVPVDPR-VLIAUNLRSA-N (2s,3r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[(2-methylpropan-2-yl)oxy]butanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H]([C@H](OC(C)(C)C)C)C(O)=O)C3=CC=CC=C3C2=C1 LZOLWEQBVPVDPR-VLIAUNLRSA-N 0.000 description 1
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
DHBXNPKRAUYBTH-UHFFFAOYSA-N 1,1-ethanedithiol Chemical compound CC(S)S DHBXNPKRAUYBTH-UHFFFAOYSA-N 0.000 description 1
ZPGDWQNBZYOZTI-UHFFFAOYSA-N 1-(9h-fluoren-9-ylmethoxycarbonyl)pyrrolidine-2-carboxylic acid Chemical compound OC(=O)C1CCCN1C(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 ZPGDWQNBZYOZTI-UHFFFAOYSA-N 0.000 description 1
GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
102000007469 Actins Human genes 0.000 description 1
108010085238 Actins Proteins 0.000 description 1
HXNNRBHASOSVPG-GUBZILKMSA-N Ala-Glu-Leu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O HXNNRBHASOSVPG-GUBZILKMSA-N 0.000 description 1
OYJCVIGKMXUVKB-GARJFASQSA-N Ala-Leu-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N OYJCVIGKMXUVKB-GARJFASQSA-N 0.000 description 1
YCTIYBUTCKNOTI-UWJYBYFXSA-N Ala-Tyr-Asp Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)N YCTIYBUTCKNOTI-UWJYBYFXSA-N 0.000 description 1
MUGAESARFRGOTQ-IGNZVWTISA-N Ala-Tyr-Tyr Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)N MUGAESARFRGOTQ-IGNZVWTISA-N 0.000 description 1
108700028369 Alleles Proteins 0.000 description 1
102100023635 Alpha-fetoprotein Human genes 0.000 description 1
238000006677 Appel reaction Methods 0.000 description 1
JAYIQMNQDMOBFY-KKUMJFAQSA-N Arg-Glu-Tyr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O JAYIQMNQDMOBFY-KKUMJFAQSA-N 0.000 description 1
UGZUVYDKAYNCII-ULQDDVLXSA-N Arg-Phe-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O UGZUVYDKAYNCII-ULQDDVLXSA-N 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
241000219198 Brassica Species 0.000 description 1
235000003351 Brassica cretica Nutrition 0.000 description 1
235000003343 Brassica rupestris Nutrition 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
241000283707 Capra Species 0.000 description 1
206010008909 Chronic Hepatitis Diseases 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
MUSGDMDGNGXULI-DCAQKATOSA-N Glu-Glu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O MUSGDMDGNGXULI-DCAQKATOSA-N 0.000 description 1
YSWHPLCDIMUKFE-QWRGUYRKSA-N Glu-Tyr Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 YSWHPLCDIMUKFE-QWRGUYRKSA-N 0.000 description 1
MXXXVOYFNVJHMA-IUCAKERBSA-N Gly-Arg-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CN MXXXVOYFNVJHMA-IUCAKERBSA-N 0.000 description 1
DKEXFJVMVGETOO-LURJTMIESA-N Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CN DKEXFJVMVGETOO-LURJTMIESA-N 0.000 description 1
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
238000012752 Hepatectomy Methods 0.000 description 1
102100031000 Hepatoma-derived growth factor Human genes 0.000 description 1
101001083798 Homo sapiens Hepatoma-derived growth factor Proteins 0.000 description 1
101710123134 Ice-binding protein Proteins 0.000 description 1
108700005091 Immunoglobulin Genes Proteins 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
102100037850 Interferon gamma Human genes 0.000 description 1
108010074328 Interferon-gamma Proteins 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
SQXUUGUCGJSWCK-CIUDSAMLSA-N Lys-Asp-Cys Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CS)C(=O)O)N SQXUUGUCGJSWCK-CIUDSAMLSA-N 0.000 description 1
LUAJJLPHUXPQLH-KKUMJFAQSA-N Lys-Phe-Ser Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCCCN)N LUAJJLPHUXPQLH-KKUMJFAQSA-N 0.000 description 1
USPJSTBDIGJPFK-PMVMPFDFSA-N Lys-Tyr-Trp Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O USPJSTBDIGJPFK-PMVMPFDFSA-N 0.000 description 1
102000043129 MHC class I family Human genes 0.000 description 1
108091054437 MHC class I family Proteins 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
NLDXSXDCNZIQCN-ULQDDVLXSA-N Met-Phe-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCSC)CC1=CC=CC=C1 NLDXSXDCNZIQCN-ULQDDVLXSA-N 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
101710116850 Molybdenum cofactor sulfurase 2 Proteins 0.000 description 1
241000699660 Mus musculus Species 0.000 description 1
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
108700020796 Oncogene Proteins 0.000 description 1
GKZIWHRNKRBEOH-HOTGVXAUSA-N Phe-Phe Chemical compound C([C@H]([NH3+])C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)C1=CC=CC=C1 GKZIWHRNKRBEOH-HOTGVXAUSA-N 0.000 description 1
RAGOJJCBGXARPO-XVSYOHENSA-N Phe-Thr-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H]([C@H](O)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 RAGOJJCBGXARPO-XVSYOHENSA-N 0.000 description 1
APMXLWHMIVWLLR-BZSNNMDCSA-N Phe-Tyr-Ser Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(O)=O)C1=CC=CC=C1 APMXLWHMIVWLLR-BZSNNMDCSA-N 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
MGDFPGCFVJFITQ-CIUDSAMLSA-N Pro-Glu-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O MGDFPGCFVJFITQ-CIUDSAMLSA-N 0.000 description 1
LNICFEXCAHIJOR-DCAQKATOSA-N Pro-Ser-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O LNICFEXCAHIJOR-DCAQKATOSA-N 0.000 description 1
229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
206010070308 Refractory cancer Diseases 0.000 description 1
241000239226 Scorpiones Species 0.000 description 1
RRVFEDGUXSYWOW-BZSNNMDCSA-N Ser-Phe-Phe Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O RRVFEDGUXSYWOW-BZSNNMDCSA-N 0.000 description 1
PZHJLTWGMYERRJ-SRVKXCTJSA-N Ser-Tyr-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CO)N)O PZHJLTWGMYERRJ-SRVKXCTJSA-N 0.000 description 1
108010090804 Streptavidin Proteins 0.000 description 1
230000005867 T cell response Effects 0.000 description 1
STJXERBCEWQLKS-IHPCNDPISA-N Trp-Tyr-Cys Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)N)C(=O)N[C@@H](CS)C(O)=O)C1=CC=C(O)C=C1 STJXERBCEWQLKS-IHPCNDPISA-N 0.000 description 1
101710107540 Type-2 ice-structuring protein Proteins 0.000 description 1
YRBHLWWGSSQICE-IHRRRGAJSA-N Tyr-Asp-Met Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(O)=O YRBHLWWGSSQICE-IHRRRGAJSA-N 0.000 description 1
VHIZXDZMTDVFGX-DCAQKATOSA-N Val-Ser-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)N VHIZXDZMTDVFGX-DCAQKATOSA-N 0.000 description 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
241000700605 Viruses Species 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000032683 aging Effects 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
230000003321 amplification Effects 0.000 description 1
230000002668 anti-heparin effect Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
239000011324 bead Substances 0.000 description 1
210000000013 bile duct Anatomy 0.000 description 1
QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
230000007969 cellular immunity Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
238000012258 culturing Methods 0.000 description 1
108010016616 cysteinylglycine Proteins 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
238000000432 density-gradient centrifugation Methods 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
229910003460 diamond Inorganic materials 0.000 description 1
239000010432 diamond Substances 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000013399 early diagnosis Methods 0.000 description 1
239000012636 effector Substances 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
210000003238 esophagus Anatomy 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000012634 fragment Substances 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
108010057083 glutamyl-aspartyl-leucine Proteins 0.000 description 1
229930182470 glycoside Natural products 0.000 description 1
XBGGUPMXALFZOT-UHFFFAOYSA-N glycyl-L-tyrosine hemihydrate Natural products NCC(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-UHFFFAOYSA-N 0.000 description 1
108010050848 glycylleucine Proteins 0.000 description 1
108010087823 glycyltyrosine Proteins 0.000 description 1
229960004198 guanidine Drugs 0.000 description 1
OJDNFXUNDNXMPS-UHFFFAOYSA-N guanidine;2-sulfanylacetic acid Chemical compound NC(N)=N.OC(=O)CS OJDNFXUNDNXMPS-UHFFFAOYSA-N 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
102000048373 human GPC3 Human genes 0.000 description 1
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
230000036039 immunity Effects 0.000 description 1
230000003053 immunization Effects 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
238000003125 immunofluorescent labeling Methods 0.000 description 1
239000003547 immunosorbent Substances 0.000 description 1
238000012744 immunostaining Methods 0.000 description 1
238000000126 in silico method Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
125000003473 lipid group Chemical group 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000007791 liquid phase Substances 0.000 description 1
201000007270 liver cancer Diseases 0.000 description 1
208000014018 liver neoplasm Diseases 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
238000005259 measurement Methods 0.000 description 1
239000002609 medium Substances 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
229960004452 methionine Drugs 0.000 description 1
108010056582 methionylglutamic acid Proteins 0.000 description 1
239000000203 mixture Substances 0.000 description 1
239000003068 molecular probe Substances 0.000 description 1
210000005087 mononuclear cell Anatomy 0.000 description 1
235000010460 mustard Nutrition 0.000 description 1
201000000050 myeloid neoplasm Diseases 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
238000010606 normalization Methods 0.000 description 1
230000001473 noxious effect Effects 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
102000013415 peroxidase activity proteins Human genes 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
238000005502 peroxidation Methods 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
239000012071 phase Substances 0.000 description 1
108010073025 phenylalanylphenylalanine Proteins 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
238000010837 poor prognosis Methods 0.000 description 1
230000002980 postoperative effect Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
239000012474 protein marker Substances 0.000 description 1
238000000163 radioactive labelling Methods 0.000 description 1
208000016691 refractory malignant neoplasm Diseases 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
210000003296 saliva Anatomy 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
239000012679 serum free medium Substances 0.000 description 1
108010069117 seryl-lysyl-aspartic acid Proteins 0.000 description 1
235000020183 skimmed milk Nutrition 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000010189 synthetic method Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
HNKJADCVZUBCPG-UHFFFAOYSA-N thioanisole Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
230000009261 transgenic effect Effects 0.000 description 1
238000011830 transgenic mouse model Methods 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
230000005740 tumor formation Effects 0.000 description 1
108010020532 tyrosyl-proline Proteins 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
238000002255 vaccination Methods 0.000 description 1
239000004474 valine Substances 0.000 description 1
230000009790 vascular invasion Effects 0.000 description 1
230000009278 visceral effect Effects 0.000 description 1
230000000007 visual effect Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4725—Proteoglycans, e.g. aggreccan
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Urology & Nephrology (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Hematology (AREA)
Biochemistry (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
General Physics & Mathematics (AREA)
Oncology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Zoology (AREA)
Cell Biology (AREA)
Toxicology (AREA)
Microbiology (AREA)
Food Science & Technology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Hospice & Palliative Care (AREA)
Pathology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

TW092122744A 2002-08-26 2003-08-19 Peptides and drugs containing the same TW200413406A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP2002245831		2002-08-26

Publications (2)

Publication Number	Publication Date
TW200413406A TW200413406A (en)	2004-08-01
TWI333958B true TWI333958B (fr)	2010-12-01

Family

ID=31944202

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW092122744A TW200413406A (en)	2002-08-26	2003-08-19	Peptides and drugs containing the same

Country Status (4)

Country	Link
JP (1)	JP4406607B2 (fr)
AU (1)	AU2003254950A1 (fr)
TW (1)	TW200413406A (fr)
WO (1)	WO2004018667A1 (fr)

Families Citing this family (131)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR100786054B1 (ko)	2002-03-25	2007-12-17	다카라 바이오 가부시키가이샤	세포상해성 림프구의 제조방법
EA012520B1 (ru)	2003-08-22	2009-10-30	Такара Био Инк.	Способ получения цитотоксических лимфоцитов
JP4658926B2 (ja)	2004-04-28	2011-03-23	株式会社ペルセウスプロテオミクス	肝癌治療後の再発予測判定薬
PT1674111E (pt)	2004-07-09	2010-12-15	Chugai Pharmaceutical Co Ltd	Anticorpo anti-glipicano 3
KR20130103580A (ko)	2004-08-24	2013-09-23	추가이 세이야쿠 가부시키가이샤	항 글리피칸 3 항체를 이용한 어쥬번트 요법
AU2005297772B2 (en)	2004-10-26	2011-06-23	Chugai Seiyaku Kabushiki Kaisha	Anti-glypican 3 antibody having modified sugar chain
PT1855707E (pt)	2005-02-28	2012-05-25	Oncotherapy Science Inc	Péptidos de epítopo derivados de receptor de factor de crescimento endotelial vascular 1 e vacinas contendo estes péptidos
RU2449020C2 (ru) *	2005-07-27	2012-04-27	Онкотерапи Сайенс, Инк.	Связанный с раком толстого кишечника ген том34
WO2007018199A1 (fr) *	2005-08-09	2007-02-15	Kumamoto University	Peptide antigène dérivé du glypican-3 (gpc3) pour une utilisation chez des patients positifs à l’hal-a2 et produit pharmaceutique comprenant l’antigène
KR101279172B1 (ko)	2005-08-17	2013-06-27	다카라 바이오 가부시키가이샤	림프구의 제조 방법
KR101408565B1 (ko) *	2005-09-30	2014-06-17	다카라 바이오 가부시키가이샤	Ｔ 세포 집단의 제조 방법
US20070087005A1 (en)	2005-10-14	2007-04-19	Lazar Gregory A	Anti-glypican-3 antibody
AU2007283731B2 (en) *	2006-08-11	2013-10-24	Katholieke Universiteit Leuven	Immunogenic peptides and their use in immune disorders
MX2009008104A (es)	2007-02-02	2009-08-07	Amgen Inc	Hepcidina, antagonistas de hepcidina y metodos de uso.
ES2750254T3 (es)	2007-09-27	2020-03-25	Amgen Inc	Formulaciones farmacéuticas
EP3381445B1 (fr)	2007-11-15	2023-10-25	Amgen Inc.	Formulation aqueuse d'anticorps stabilisée par des antioxydants pour administration parentérale
TW200932260A (en) *	2007-11-28	2009-08-01	Oncotherapy Science Inc	STAT3 epitope peptides
US9175078B2 (en)	2008-01-25	2015-11-03	Amgen Inc.	Ferroportin antibodies and methods of use
EP2244733B1 (fr)	2008-02-14	2015-06-17	Life Sciences Research Partners VZW	Immunothérapie ciblant des agents pathogènes intracellulaires
ES2545885T3 (es)	2008-02-14	2015-09-16	Life Sciences Research Partners Vzw	Eliminación de respuestas inmunitarias contra vectores virales
ES2627882T3 (es)	2008-02-14	2017-07-31	Life Sciences Research Partners Vzw	Control inmunogénico de tumores y células tumorales
AU2009214041A1 (en)	2008-02-14	2009-08-20	Katholieke Universiteit Leuven	CD4+ T-cells with cytolytic properties
EP2620448A1 (fr)	2008-05-01	2013-07-31	Amgen Inc.	Anticorps anti-hepcidine et méthodes d'utilisation associées
TW201000119A (en) *	2008-06-10	2010-01-01	Oncotherapy Science Inc	MYBL2 epitope peptides and vaccines containing the same
CA3019967A1 (fr)	2008-11-13	2010-05-20	The General Hospital Corporation	Procedes et compositions pour la regulation de l'homeostasie du fer par modulation de la proteine bmp-6
US9662271B2 (en)	2009-10-23	2017-05-30	Amgen Inc.	Vial adapter and system
CA2800919C (fr)	2010-06-07	2019-01-15	Amgen Inc.	Dispositif d'administration de medicament
BR112013005448A2 (pt) *	2010-09-07	2019-09-24	Oncotherapy Science Inc	peptídeos de ttll4 e vacinas contendo os mesmos.
EP2630237A4 (fr) *	2010-10-21	2014-04-09	Oncotherapy Science Inc	Peptides c18orf54 et vaccins les contenant
TW201216982A (en)	2010-10-21	2012-05-01	Oncotherapy Science Inc	WDHD1 peptides and vaccines including the same
DE11787873T1 (de)	2010-11-25	2013-12-12	Imnate Sarl	Immugene Peptide zur Verwendung bei der Vorbeugung und/oder Behandlung von Infektionskrankheiten, Autoimmunerkrankungen, Immunreaktionen auf Allofaktoren, allergischen Erkrankungen, Tumoren, Transplantatabstossungen und Immunreaktionen auf virale Vektoren
CN103339253B (zh)	2010-12-02	2015-09-09	肿瘤疗法科学股份有限公司	Tomm34肽及包含它们的疫苗
CA2831100C (fr)	2011-03-31	2020-02-18	Mark Dominis Holt	Adaptateur de flacon et systeme
CA2833748C (fr)	2011-04-20	2019-07-16	Amgen Inc.	Appareil auto-injecteur
LT3045189T (lt)	2011-10-14	2018-06-25	Amgen Inc.	Inžektorius ir surinkimo būdas
GB201201511D0 (en)	2012-01-30	2012-03-14	Univ Leuven Kath	Modified epitopes for boosting CD4+ T-cell responses
US20150359864A1 (en)	2012-03-09	2015-12-17	Oncotherapy Science, Inc.	Pharmaceutical composition containing peptides
US12115341B2 (en)	2012-11-21	2024-10-15	Amgen Inc.	Drug delivery device
CA2840937A1 (fr) *	2013-02-05	2014-08-05	Nitto Denko Corporation	Composition de vaccin pour administration transdermique
JP2014169275A (ja) *	2013-02-05	2014-09-18	Nitto Denko Corp	粘膜投与用ワクチン組成物
CA2904661C (fr)	2013-03-15	2022-03-15	Amgen Inc.	Boite a medicament, autoinjecteur et systeme d'autoinjecteur
AU2014228177B2 (en)	2013-03-15	2018-04-26	Amgen Inc.	Body contour adaptable autoinjector device
JP6463331B2 (ja)	2013-03-15	2019-01-30	イントリンシックライフサイエンシズリミテッドライアビリティカンパニー	抗ヘプシジン抗体およびその使用
EP2968760B1 (fr)	2013-03-15	2024-01-03	Amgen Inc.	Cartouche à médicament, auto-injecteur et système d'auto-injection
IL292270B2 (en)	2013-03-22	2024-04-01	Amgen Inc	Injector and method of assembly
GB201309469D0 (en)	2013-05-28	2013-07-10	Imcyse Sa	Detection of CD4+ T lymphocytes
SG11201602876WA (en)	2013-10-24	2016-05-30	Amgen Inc	Injector and method of assembly
MX2016005315A (es)	2013-10-24	2016-08-11	Amgen Inc	Sistema de administracion de farmacos con control sensible a la temperatura.
WO2015119906A1 (fr)	2014-02-05	2015-08-13	Amgen Inc.	Système d'administration de médicament doté d'un générateur de champ électromagnétique
KR102496507B1 (ko)	2014-05-07	2023-02-03	암겐 인코포레이티드	충격 감소 요소들을 가진 자동 주사기
KR20220143782A (ko)	2014-06-03	2022-10-25	암겐 인코포레이티드	약물 전달 디바이스의 사용자를 보조하기 위한 디바이스들 및 방법들
AU2015321462B2 (en)	2014-09-22	2020-04-30	Intrinsic Lifesciences Llc	Humanized anti-hepcidin antibodies and uses thereof
MA40764A (fr)	2014-09-26	2017-08-01	Chugai Pharmaceutical Co Ltd	Agent thérapeutique induisant une cytotoxicité
EP3205661B1 (fr)	2014-10-07	2021-07-07	Cytlimic Inc.	Peptide dérivé de hsp70 induisant l'immunité
MX2021014323A (es)	2014-10-14	2023-02-02	Amgen Inc	Dispositivo de inyección de fármaco con indicadores visuales y audibles.
TW201636358A (zh) *	2014-12-09	2016-10-16	腫瘤療法科學股份有限公司	對於ｔｈ１細胞之ｇｐｃ３抗原決定位胜肽及含此之疫苗
US11357916B2 (en)	2014-12-19	2022-06-14	Amgen Inc.	Drug delivery device with live button or user interface field
EP3848072A1 (fr)	2014-12-19	2021-07-14	Amgen Inc.	Dispositif d'administration de médicament comportant un capteur de proximité
GB201501017D0 (en) *	2014-12-23	2015-03-04	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
SG10202102698VA (en)	2014-12-23	2021-04-29	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers
CA3069716C (fr)	2015-02-17	2021-11-09	Amgen Inc.	Dispositif d'administration de medicament a securisation assistee par depression et/ou retour d'informations
US11806509B2 (en)	2015-02-27	2023-11-07	Amgen Inc.	Drug delivery device having a needle guard mechanism with a turnable threshold of resistance to needle guard movement
AU2016230125B2 (en)	2015-03-09	2020-07-16	Nec Corporation	Peptide derived from GPC3, pharmaceutical composition for treatment or prevention of cancer using same, immunity inducer, and method for producing antigen-presenting cells
EP3281641B1 (fr)	2015-04-07	2020-12-16	Cytlimic Inc.	Adjuvant pour les vaccins contre le cancer
US10729791B2 (en)	2015-05-18	2020-08-04	Imcyse Sa	Animal models for evaluating pharmaceutical compounds
WO2017039786A1 (fr)	2015-09-02	2017-03-09	Amgen Inc.	Adaptateur d'ensemble de seringue pour une seringue
EP3939606A3 (fr)	2015-09-25	2022-04-20	ImCyse SA	Composés et procédés améliorés permettant de supprimer des réponses immunitaires à des agents thérapeutiques
EP3386573B1 (fr)	2015-12-09	2019-10-02	Amgen Inc.	Auto-injecteur avec capuchon de signalisation
WO2017120178A1 (fr)	2016-01-06	2017-07-13	Amgen Inc.	Auto-injecteur pourvu d'une électronique de signalisation
DK3429663T3 (da)	2016-03-15	2020-09-28	Amgen Inc	Reduktion af sandsynligheden for glasbrud i anordninger til indgivelse af lægemidler
CA3019266A1 (fr)	2016-04-19	2017-10-26	Imcyse Sa	Nouveaux peptides immunogenes se liant au cd1d
US11541168B2 (en)	2016-04-29	2023-01-03	Amgen Inc.	Drug delivery device with messaging label
US11389588B2 (en)	2016-05-02	2022-07-19	Amgen Inc.	Syringe adapter and guide for filling an on-body injector
WO2017197222A1 (fr)	2016-05-13	2017-11-16	Amgen Inc.	Ensemble manchon de flacon
WO2017200989A1 (fr)	2016-05-16	2017-11-23	Amgen Inc.	Chiffrement de données dans des dispositifs médicaux à capacité de calcul limitée
US11541176B2 (en)	2016-06-03	2023-01-03	Amgen Inc.	Impact testing apparatuses and methods for drug delivery devices
WO2018004842A1 (fr)	2016-07-01	2018-01-04	Amgen Inc.	Dispositif d'administration de médicament présentant un risque réduit au minimum de fracture de composant lors d'événements d'impact
US20190328965A1 (en)	2016-08-17	2019-10-31	Amgen Inc.	Drug delivery device with placement detection
BR112019006075A2 (pt)	2016-10-11	2019-06-18	Cytlimic Inc	medicamento
EP3532127A1 (fr)	2016-10-25	2019-09-04	Amgen Inc.	Injecteur porté sur le corps
JP2018093823A (ja)	2016-12-15	2018-06-21	Ｈｅａｒｔｓｅｅｄ株式会社	未分化幹細胞除去剤及び未分化幹細胞除去方法
JP2020503976A (ja)	2017-01-17	2020-02-06	アムジエン・インコーポレーテツド	注入デバイスならびに関連する使用および組立方法
TW201835100A (zh)	2017-02-06	2018-10-01	國立研究開發法人國立癌症研究中心	新穎ｔ細胞受體
CA3048520A1 (fr)	2017-02-17	2018-08-23	Amgen Inc.	Dispositif d'administration de medicament a trajet d'ecoulement de fluide sterile et procede d'assemblage associe
EP3582829A1 (fr)	2017-02-17	2019-12-25	Amgen Inc.	Mécanisme d'insertion pour dispositif d'administration de médicament
JP2020508803A (ja)	2017-03-06	2020-03-26	アムジエン・インコーポレーテツド	作動防止特徴部を備える薬物送達デバイス
US11571511B2 (en)	2017-03-07	2023-02-07	Amgen Inc.	Insertion mechanism and method of inserting a needle of a drug delivery device
KR102893480B1 (ko)	2017-03-09	2025-11-28	암겐 인코포레이티드	약물 전달 장치용 삽입 메커니즘
CN110446499A (zh)	2017-03-20	2019-11-12	豪夫迈·罗氏有限公司	一种体外糖基工程化红细胞生成刺激蛋白的方法
HUE063805T2 (hu)	2017-03-28	2024-01-28	Amgen Inc	Dugattyúrúd és fecskendõ összeállító rendszer és eljárás
AU2018282077B2 (en)	2017-06-08	2023-11-23	Amgen Inc.	Torque driven drug delivery device
CA3061982A1 (fr)	2017-06-08	2018-12-13	Amgen Inc.	Ensemble de seringue d'un appareil d'administration de medicament et procede d'assemblage
MA49447A (fr)	2017-06-22	2020-04-29	Amgen Inc	Réduction des impacts/chocs d'activation d'un dispositif
WO2018237225A1 (fr)	2017-06-23	2018-12-27	Amgen Inc.	Dispositif électronique d'administration de médicament comprenant un bouchon activé par un ensemble commutateur
MA49562A (fr)	2017-07-14	2020-05-20	Amgen Inc	Système d'insertion-rétractation d'aiguille présentant un système à ressort en double torsion
MA49626A (fr)	2017-07-21	2020-05-27	Amgen Inc	Élément d'étanchéité perméable aux gaz pour récipient à médicament et procédés d'assemblage
JP2020528296A (ja)	2017-07-25	2020-09-24	アムジエン・インコーポレーテツド	ギヤモジュールを有する薬物送達デバイス及び関連する組立方法
WO2019022950A1 (fr)	2017-07-25	2019-01-31	Amgen Inc.	Dispositif d'administration de médicament doté d'un système d'accès à un récipient et procédé d'assemblage associé
MA49838A (fr)	2017-08-09	2020-06-17	Amgen Inc	Systèm de administration de médicaments avec pression hydraulique-pneumatique de chambre
US11077246B2 (en)	2017-08-18	2021-08-03	Amgen Inc.	Wearable injector with sterile adhesive patch
US11103636B2 (en)	2017-08-22	2021-08-31	Amgen Inc.	Needle insertion mechanism for drug delivery device
ES2939292T3 (es)	2017-10-04	2023-04-20	Amgen Inc	Adaptador de flujo para dispositivo de administración de fármacos
EP3691716B1 (fr)	2017-10-06	2023-11-29	Amgen Inc.	Dispositif d'administration de médicament comprenant un ensemble de verrouillage et procédé d'assemblage associé
US11464903B2 (en)	2017-10-09	2022-10-11	Amgen Inc.	Drug delivery device with drive assembly and related method of assembly
WO2019090079A1 (fr)	2017-11-03	2019-05-09	Amgen Inc.	Système et approches pour stériliser un dispositif d'administration de médicament
JP2021501616A (ja)	2017-11-06	2021-01-21	アムジエン・インコーポレーテツド	配置及び流量検出を備える薬物送達デバイス
US12053618B2 (en)	2017-11-06	2024-08-06	Amgen Inc.	Fill-finish assemblies and related methods
MA50557A (fr)	2017-11-10	2020-09-16	Amgen Inc	Pistons pour dispositifs d'administration de médicament
WO2019099322A1 (fr)	2017-11-16	2019-05-23	Amgen Inc.	Auto-injecteur avec détection de décrochage et de point d'extrémité
IL273638B2 (en)	2017-11-16	2024-10-01	Amgen Inc	Door latch mechanism for drug delivery device
US10835685B2 (en)	2018-05-30	2020-11-17	Amgen Inc.	Thermal spring release mechanism for a drug delivery device
US11083840B2 (en)	2018-06-01	2021-08-10	Amgen Inc.	Modular fluid path assemblies for drug delivery devices
CA3103682A1 (fr)	2018-07-24	2020-01-30	Amgen Inc.	Dispositifs d'administration pour l'administration de medicaments
MA53379A (fr)	2018-07-24	2021-06-02	Amgen Inc	Dispositifs d'administration pour l'administration de médicaments
WO2020023220A1 (fr)	2018-07-24	2020-01-30	Amgen Inc.	Dispositifs d'administration de médicament hybrides dotés d'une partie de fixation collante à placer sur la peau et procédé de préparation associé
WO2020023336A1 (fr)	2018-07-24	2020-01-30	Amgen Inc.	Dispositifs hybrides d'administration de médicament dotés d'une partie de préhension
MA53320A (fr)	2018-07-31	2021-11-03	Amgen Inc	Ensemble de trajet de fluide pour dispositif d'administration de médicament
AU2019347710B2 (en)	2018-09-24	2025-05-08	Amgen Inc.	Interventional dosing systems and methods
IL281469B2 (en)	2018-09-28	2024-08-01	Amgen Inc	Muscle wire escapement activation assembly for a drug delivery device
US12156991B2 (en)	2018-10-02	2024-12-03	Amgen Inc.	Injection systems for drug delivery with internal force transmission
WO2020072846A1 (fr)	2018-10-05	2020-04-09	Amgen Inc.	Dispositif d'administration de médicament ayant un indicateur de dose
WO2020081480A1 (fr)	2018-10-15	2020-04-23	Amgen Inc.	Procédé d'assemblage de plate-forme pour dispositif d'administration de médicament
US12053617B2 (en)	2018-10-15	2024-08-06	Amgen Inc.	Drug delivery device having damping mechanism
US11213620B2 (en)	2018-11-01	2022-01-04	Amgen Inc.	Drug delivery devices with partial drug delivery member retraction
TWI831847B (zh)	2018-11-01	2024-02-11	美商安進公司	部分針頭縮回之藥物遞送裝置及其操作方法
US12485219B2 (en)	2018-11-01	2025-12-02	Amgen Inc.	Drug delivery devices with partial drug delivery member retraction
ES3032751T3 (en)	2019-04-24	2025-07-24	Amgen Inc	Syringe sterilization verification assemblies and methods
MX2022002149A (es)	2019-08-23	2022-03-17	Amgen Inc	Dispositivo de suministro de farmacos con componentes de acoplamiento de capuchon de aguja configurable y metodos relacionados.
CN115960205A (zh) *	2019-12-13	2023-04-14	南京大户生物科技有限公司	原发性肝癌相关抗原的胸腺依赖性淋巴细胞抗原表位肽及其应用
KR20240011135A (ko)	2021-05-21	2024-01-25	암젠 인크	약물 용기를 위한 충전 레시피를 최적화하는 방법
AU2023374183A1 (en)	2022-11-02	2025-03-20	F. Hoffmann-La Roche Ag	Method for producing glycoprotein compositions

2003
- 2003-08-19 JP JP2004530567A patent/JP4406607B2/ja not_active Expired - Lifetime
- 2003-08-19 AU AU2003254950A patent/AU2003254950A1/en not_active Abandoned
- 2003-08-19 TW TW092122744A patent/TW200413406A/zh not_active IP Right Cessation
- 2003-08-19 WO PCT/JP2003/010459 patent/WO2004018667A1/fr not_active Ceased

Also Published As

Publication number	Publication date
JPWO2004018667A1 (ja)	2005-12-08
AU2003254950A1 (en)	2004-03-11
WO2004018667A1 (fr)	2004-03-04
JP4406607B2 (ja)	2010-02-03
TW200413406A (en)	2004-08-01

Publication	Publication Date	Title
TWI333958B (fr)	2010-12-01
CA2940962C (fr)	2018-07-24	Composition de vaccin contre le cancer
JP2019122377A (ja)	2019-07-25	免疫原性ｗｔ−１ペプチドおよびその使用法
JP2007516966A (ja)	2007-06-28	合成ｈｌａ結合ペプチド類似体及びその使用方法
RS62237B1 (sr)	2021-09-30	Novi peptidi i kombinacija peptida za upotrebu u imunoterapiji protiv hepatocelularnog karcinoma (hcc) i drugih malignih tumora
CN102481333B (zh)	2017-07-14	免疫诱导剂
TW201043240A (en)	2010-12-16	NEIL3 peptides and vaccines including the same
TW201138806A (en)	2011-11-16	CDCA5 peptides and vaccines including the same
CN101072875B (zh)	2011-05-18	新型癌抗原肽及其用途
TW201225973A (en)	2012-07-01	Tomm34 peptides and vaccines including the same
RS62575B1 (sr)	2021-12-31	Novi peptidi i kombinacija peptida za upotrebu u imunoterapiji protiv hepatocelularnog karcinoma (hcc) i drugih malignih tumora
TW201200525A (en)	2012-01-01	MYBL2 peptides and vaccines containing the same
TW201138803A (en)	2011-11-16	ECT2 peptides and vaccines including the same
WO2024262558A1 (fr)	2024-12-26	Peptide d'antigène tumoral codé par un gène de rétrovirus endogène humain
HK1143552B (en)	2019-05-17	Cancer vaccine composition
HK1261028A1 (en)	2019-12-27	Cancer vaccine composition
HK1261028B (en)	2025-04-25	Cancer vaccine composition
HK1143552A (en)	2011-01-07	Cancer vaccine composition
TW201134480A (en)	2011-10-16	CLUAP1 peptides and vaccines including the same

Legal Events

Date	Code	Title	Description
2023-10-01	MK4A	Expiration of patent term of an invention patent